Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BullFrog AI Holdings, Inc.BFRG · Entity 8036 | Director | June 11, 2026 | June 15, 2026 |
| enGene Therapeutics Inc.ENGN · Entity 6638 | Director · Chief Executive Officer | October 31, 2023 | November 02, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BullFrog AI Holdings, Inc.
Report date June 11, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.63 | Direct | 15,000 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 15,000 · Balance 15,000 F3: The options were issued as a grant under the Plan, based on the market price on the date of the grant. F1: Represents stock options issued under BullFrog AI Holdings, Inc.'s (the "Company") 2022 Equity Compensation Plan, as amended from time to time (the "Plan"), which vest on June 11, 2027. Lapse of forfeiture restrictions will accelerate upon a change in control of the Company (as defined in the Plan) or a significant financing, which may, or may not, constitute a change in control. F2: The stock options expire on June 12, 2036. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents stock options issued under BullFrog AI Holdings, Inc.'s (the "Company") 2022 Equity Compensation Plan, as amended from time to time (the "Plan"), which vest on June 11, 2027. Lapse of forfeiture restrictions will accelerate upon a change in control of the Company (as defined in the Plan) or a significant financing, which may, or may not, constitute a change in control.
F2: The stock options expire on June 12, 2036.
F3: The options were issued as a grant under the Plan, based on the market price on the date of the grant.
enGene Therapeutics Inc.
Report date October 31, 2023 · Filed November 02, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.88 · Expires 2028-07-09 | Direct | 137,051 |
Reported balance
After 2018-07-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-07-09 · Grant · Acquired 137,051 · Balance 137,051 F1: On October 31, 2023 (the "Closing Date"), the parties to the Business Combination Agreement, dated as of May 16, 2023 (as amended, the "Business Combination Agreement"), by and among Forbion European Acquisition Corp., a Cayman Islands exempted company and a special purpose acquisition corporation ("FEAC"), enGene Inc., a corporation incorporated under the laws of Canada ("enGene"), and enGene Holdings Inc. (the "Issuer" or "New enGene"), completed the transactions contemplated thereby, pursuant to which (i) each share of FEAC was exchanged on a one for one basis for a share of New enGene, and (ii) each share of enGene was exchanged for 0.1804799669 shares of New enGene, and each of FEAC and enGene became wholly-owned subsidiaries of New enGene. The transactions contemplated by the Business Combination Agreement are referred to herein as the "Business Combination". F2: Pursuant to the terms of the Business Combination, the shareholders of enGene received 0.1804799669 common shares of the Issuer ("Common Shares") for each share of enGene held by them immediately prior to the Closing Date. Upon the Closing of the Business Combination, all outstanding enGene options were assumed by New enGene. enGene options that were issued or available to be issued as of May 16, 2023 were accelerated and become vested and exercisable (if not previously vested and exercisable). The issuance of the securities to the Reporting Person was approved by the Issuer's board of directors in the manner contemplated by Rule 16b-3 under the Securities Exchange Act of 1934, as amended. F3: This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 759,374 common shares of enGene. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.88 · Expires 2029-07-30 | Direct | 30,939 |
Reported balance
After 2019-07-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-07-30 · Grant · Acquired 30,939 · Balance 30,939 F1: On October 31, 2023 (the "Closing Date"), the parties to the Business Combination Agreement, dated as of May 16, 2023 (as amended, the "Business Combination Agreement"), by and among Forbion European Acquisition Corp., a Cayman Islands exempted company and a special purpose acquisition corporation ("FEAC"), enGene Inc., a corporation incorporated under the laws of Canada ("enGene"), and enGene Holdings Inc. (the "Issuer" or "New enGene"), completed the transactions contemplated thereby, pursuant to which (i) each share of FEAC was exchanged on a one for one basis for a share of New enGene, and (ii) each share of enGene was exchanged for 0.1804799669 shares of New enGene, and each of FEAC and enGene became wholly-owned subsidiaries of New enGene. The transactions contemplated by the Business Combination Agreement are referred to herein as the "Business Combination". F2: Pursuant to the terms of the Business Combination, the shareholders of enGene received 0.1804799669 common shares of the Issuer ("Common Shares") for each share of enGene held by them immediately prior to the Closing Date. Upon the Closing of the Business Combination, all outstanding enGene options were assumed by New enGene. enGene options that were issued or available to be issued as of May 16, 2023 were accelerated and become vested and exercisable (if not previously vested and exercisable). The issuance of the securities to the Reporting Person was approved by the Issuer's board of directors in the manner contemplated by Rule 16b-3 under the Securities Exchange Act of 1934, as amended. F4: This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 171,429 common shares of enGene. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.88 · Expires 2031-08-20 | Direct | 524,544 |
Reported balance
After 2021-08-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-08-20 · Grant · Acquired 524,544 · Balance 524,544 F1: On October 31, 2023 (the "Closing Date"), the parties to the Business Combination Agreement, dated as of May 16, 2023 (as amended, the "Business Combination Agreement"), by and among Forbion European Acquisition Corp., a Cayman Islands exempted company and a special purpose acquisition corporation ("FEAC"), enGene Inc., a corporation incorporated under the laws of Canada ("enGene"), and enGene Holdings Inc. (the "Issuer" or "New enGene"), completed the transactions contemplated thereby, pursuant to which (i) each share of FEAC was exchanged on a one for one basis for a share of New enGene, and (ii) each share of enGene was exchanged for 0.1804799669 shares of New enGene, and each of FEAC and enGene became wholly-owned subsidiaries of New enGene. The transactions contemplated by the Business Combination Agreement are referred to herein as the "Business Combination". F2: Pursuant to the terms of the Business Combination, the shareholders of enGene received 0.1804799669 common shares of the Issuer ("Common Shares") for each share of enGene held by them immediately prior to the Closing Date. Upon the Closing of the Business Combination, all outstanding enGene options were assumed by New enGene. enGene options that were issued or available to be issued as of May 16, 2023 were accelerated and become vested and exercisable (if not previously vested and exercisable). The issuance of the securities to the Reporting Person was approved by the Issuer's board of directors in the manner contemplated by Rule 16b-3 under the Securities Exchange Act of 1934, as amended. F5: This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 2,906,386 common shares of enGene. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.88 · Expires 2031-08-20 | Direct | 10,906 |
Reported balance
After 2021-08-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-08-20 · Grant · Acquired 10,906 · Balance 10,906 F1: On October 31, 2023 (the "Closing Date"), the parties to the Business Combination Agreement, dated as of May 16, 2023 (as amended, the "Business Combination Agreement"), by and among Forbion European Acquisition Corp., a Cayman Islands exempted company and a special purpose acquisition corporation ("FEAC"), enGene Inc., a corporation incorporated under the laws of Canada ("enGene"), and enGene Holdings Inc. (the "Issuer" or "New enGene"), completed the transactions contemplated thereby, pursuant to which (i) each share of FEAC was exchanged on a one for one basis for a share of New enGene, and (ii) each share of enGene was exchanged for 0.1804799669 shares of New enGene, and each of FEAC and enGene became wholly-owned subsidiaries of New enGene. The transactions contemplated by the Business Combination Agreement are referred to herein as the "Business Combination". F2: Pursuant to the terms of the Business Combination, the shareholders of enGene received 0.1804799669 common shares of the Issuer ("Common Shares") for each share of enGene held by them immediately prior to the Closing Date. Upon the Closing of the Business Combination, all outstanding enGene options were assumed by New enGene. enGene options that were issued or available to be issued as of May 16, 2023 were accelerated and become vested and exercisable (if not previously vested and exercisable). The issuance of the securities to the Reporting Person was approved by the Issuer's board of directors in the manner contemplated by Rule 16b-3 under the Securities Exchange Act of 1934, as amended. F6: 6. This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 60,429 common shares of enGene. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.25 · Expires 2033-07-07 | Direct | 512,826 |
Reported balance
After 2023-07-07 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-07-07 · Grant · Acquired 512,826 · Balance 512,826 F1: On October 31, 2023 (the "Closing Date"), the parties to the Business Combination Agreement, dated as of May 16, 2023 (as amended, the "Business Combination Agreement"), by and among Forbion European Acquisition Corp., a Cayman Islands exempted company and a special purpose acquisition corporation ("FEAC"), enGene Inc., a corporation incorporated under the laws of Canada ("enGene"), and enGene Holdings Inc. (the "Issuer" or "New enGene"), completed the transactions contemplated thereby, pursuant to which (i) each share of FEAC was exchanged on a one for one basis for a share of New enGene, and (ii) each share of enGene was exchanged for 0.1804799669 shares of New enGene, and each of FEAC and enGene became wholly-owned subsidiaries of New enGene. The transactions contemplated by the Business Combination Agreement are referred to herein as the "Business Combination". F2: Pursuant to the terms of the Business Combination, the shareholders of enGene received 0.1804799669 common shares of the Issuer ("Common Shares") for each share of enGene held by them immediately prior to the Closing Date. Upon the Closing of the Business Combination, all outstanding enGene options were assumed by New enGene. enGene options that were issued or available to be issued as of May 16, 2023 were accelerated and become vested and exercisable (if not previously vested and exercisable). The issuance of the securities to the Reporting Person was approved by the Issuer's board of directors in the manner contemplated by Rule 16b-3 under the Securities Exchange Act of 1934, as amended. F7: 7. This option was granted on July 7, 2023 on the condition it is not exercisable unless and until (i) the Business Combination Agreement has been completed and (ii) an effective registration statement for the New enGene shares underlying such granted options has been filed. This option was received in the Business Combination in exchange for an option to purchase 2,841,461 common shares of enGene. This option is fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: On October 31, 2023 (the "Closing Date"), the parties to the Business Combination Agreement, dated as of May 16, 2023 (as amended, the "Business Combination Agreement"), by and among Forbion European Acquisition Corp., a Cayman Islands exempted company and a special purpose acquisition corporation ("FEAC"), enGene Inc., a corporation incorporated under the laws of Canada ("enGene"), and enGene Holdings Inc. (the "Issuer" or "New enGene"), completed the transactions contemplated thereby, pursuant to which (i) each share of FEAC was exchanged on a one for one basis for a share of New enGene, and (ii) each share of enGene was exchanged for 0.1804799669 shares of New enGene, and each of FEAC and enGene became wholly-owned subsidiaries of New enGene. The transactions contemplated by the Business Combination Agreement are referred to herein as the "Business Combination".
F2: Pursuant to the terms of the Business Combination, the shareholders of enGene received 0.1804799669 common shares of the Issuer ("Common Shares") for each share of enGene held by them immediately prior to the Closing Date. Upon the Closing of the Business Combination, all outstanding enGene options were assumed by New enGene. enGene options that were issued or available to be issued as of May 16, 2023 were accelerated and become vested and exercisable (if not previously vested and exercisable). The issuance of the securities to the Reporting Person was approved by the Issuer's board of directors in the manner contemplated by Rule 16b-3 under the Securities Exchange Act of 1934, as amended.
F3: This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 759,374 common shares of enGene.
F4: This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 171,429 common shares of enGene.
F5: This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 2,906,386 common shares of enGene.
F6: 6. This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 60,429 common shares of enGene.
F7: 7. This option was granted on July 7, 2023 on the condition it is not exercisable unless and until (i) the Business Combination Agreement has been completed and (ii) an effective registration statement for the New enGene shares underlying such granted options has been filed. This option was received in the Business Combination in exchange for an option to purchase 2,841,461 common shares of enGene. This option is fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 15, 2026 21:29 UTC | BullFrog AI Holdings, Inc. BFRG · Entity 8036 | GrantStock Options (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0001493152-26-028744 · ownership.xml · derivative · entry 1 Hanson Jason David · CIK 0001368586 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires not disclosed F3 · price: The options were issued as a grant under the Plan, based on the market price on the date of the grant. F1 · derivative.exercise_date: Represents stock options issued under BullFrog AI Holdings, Inc.'s (the "Company") 2022 Equity Compensation Plan, as amended from time to time (the "Plan"), which vest on June 11, 2027. Lapse of forfeiture restrictions will accelerate upon a change in control of the Company (as defined in the Plan) or a significant financing, which may, or may not, constitute a change in control. F2 · derivative.expiration_date: The stock options expire on June 12, 2036. Read SEC document |
| September 25, 2025 Filed Sep 30, 2025 00:16 UTC | BullFrog AI Holdings, Inc. BFRG · Entity 8036 | GrantStock Options (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $1.43 | $0.00 |
DisclosureSEC source: 0001493152-25-016101 · ownership.xml · derivative · entry 1 Hanson Jason David · CIK 0001368586 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires not disclosed F3 · price: The options were issued as a grant under the Plan, based on the market price on the date of the grant. F1 · derivative.exercise_date: Represents stock options issued under Bullfrog AI Holdings, Inc.'s (the "Company") 2022 Equity Compensation Plan, as amended from time to time (the "Plan"), vesting on the earlier of September 25, 2026 and the date of the Company's annual meeting for fiscal year 2026. Lapse of forfeiture restrictions will accelerate upon a change in control of the Company (as defined in the Plan) or a significant financing which may, or may not, constitute a change in control. F2 · derivative.expiration_date: The stock options expire on September 25, 2035. Read SEC document |
| August 22, 2025 Filed Aug 26, 2025 20:05 UTC | BullFrog AI Holdings, Inc. BFRG · Entity 8036 | GrantCommon Stock | 2,813 | $0.00 | $0.00 |
DisclosureSEC source: 0001641172-25-025527 · ownership.xml · nonDerivative · entry 2 Hanson Jason David · CIK 0001368586 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,523 F2 · shares: Represents 2,813 shares of Common Stock issued as an equity grant under the Plan, fully vested upon grant. Read SEC document |
| August 22, 2025 Filed Aug 26, 2025 20:05 UTC | BullFrog AI Holdings, Inc. BFRG · Entity 8036 | GrantCommon Stock | 5,710 | $0.00 | $0.00 |
DisclosureSEC source: 0001641172-25-025527 · ownership.xml · nonDerivative · entry 1 Hanson Jason David · CIK 0001368586 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,710 F1 · shares: Represents Restricted Stock Units ("RSUs") issued under the Company's 2022 Equity Compensation Plan (the "Plan"), vesting 50% on September 1, 2026, and the remaining 50% on September 1, 2027. Lapse of forfeiture restrictions will accelerate upon a change in control of the Company (as defined in the Plan) or a significant financing which may, or may not, constitute a change in control. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Read SEC document |
| September 26, 2024 Filed Feb 12, 2025 14:00 UTC | BullFrog AI Holdings, Inc. BFRG,BFRGW · Entity 8036 | GrantStock options (right to buy) · Derivative | 15,000 | $0.00 Strike: $2.96 | $0.00 |
DisclosureSEC source: 0001493152-25-006048 · ownership.xml · derivative · entry 1 Hanson Jason David · CIK 0001368586 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common stock · 15,000 shares Expires not disclosed F1 · deemedExecutionDate: The options vest on September 26, 2025. F3 · price: The options were issued as a grant under the Company's equity incentive plan based on the market price on the date of the grant. F1 · derivative.exercise_date: The options vest on September 26, 2025. F2 · derivative.expiration_date: The options expire on September 26, 2034. Read SEC document |
| July 07, 2023 Filed Nov 2, 2023 20:09 UTC | enGene Therapeutics Inc. ENGN · Entity 6638 | GrantStock Option (Right to Buy) · Derivative | 512,826 | Not disclosed Strike: $4.25 | Not disclosed |
DisclosureSEC source: 0000929638-23-002989 · form4.xml · derivative · entry 5 Hanson Jason David · CIK 0001368586 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 512,826 Underlying: Common Shares · 512,826 shares Expires 2033-07-07 F1 · price: On October 31, 2023 (the "Closing Date"), the parties to the Business Combination Agreement, dated as of May 16, 2023 (as amended, the "Business Combination Agreement"), by and among Forbion European Acquisition Corp., a Cayman Islands exempted company and a special purpose acquisition corporation ("FEAC"), enGene Inc., a corporation incorporated under the laws of Canada ("enGene"), and enGene Holdings Inc. (the "Issuer" or "New enGene"), completed the transactions contemplated thereby, pursuant to which (i) each share of FEAC was exchanged on a one for one basis for a share of New enGene, and (ii) each share of enGene was exchanged for 0.1804799669 shares of New enGene, and each of FEAC and enGene became wholly-owned subsidiaries of New enGene. The transactions contemplated by the Business Combination Agreement are referred to herein as the "Business Combination". F2 · price: Pursuant to the terms of the Business Combination, the shareholders of enGene received 0.1804799669 common shares of the Issuer ("Common Shares") for each share of enGene held by them immediately prior to the Closing Date. Upon the Closing of the Business Combination, all outstanding enGene options were assumed by New enGene. enGene options that were issued or available to be issued as of May 16, 2023 were accelerated and become vested and exercisable (if not previously vested and exercisable). The issuance of the securities to the Reporting Person was approved by the Issuer's board of directors in the manner contemplated by Rule 16b-3 under the Securities Exchange Act of 1934, as amended. F7 · price: 7. This option was granted on July 7, 2023 on the condition it is not exercisable unless and until (i) the Business Combination Agreement has been completed and (ii) an effective registration statement for the New enGene shares underlying such granted options has been filed. This option was received in the Business Combination in exchange for an option to purchase 2,841,461 common shares of enGene. This option is fully vested. F7 · derivative.exercise_date: 7. This option was granted on July 7, 2023 on the condition it is not exercisable unless and until (i) the Business Combination Agreement has been completed and (ii) an effective registration statement for the New enGene shares underlying such granted options has been filed. This option was received in the Business Combination in exchange for an option to purchase 2,841,461 common shares of enGene. This option is fully vested. Read SEC document |
| April 16, 2023 Filed May 9, 2023 21:22 UTC | BullFrog AI Holdings, Inc. BFRG,BFRGW · Entity 8036 | GrantStock options (Right to buy) · Derivative | 40,000 | $0.00 Strike: $6.82 | $0.00 |
DisclosureSEC source: 0001493152-23-015988 · ownership.xml · derivative · entry 1 Hanson Jason David · CIK 0001368586 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common stock · 40,000 shares Expires not disclosed F1 · deemedExecutionDate: The options vest as follows: 8,888 options were deemed immediately vested and, each month thereafter 864 shares vest per month. F1 · derivative.exercise_date: The options vest as follows: 8,888 options were deemed immediately vested and, each month thereafter 864 shares vest per month. F2 · derivative.expiration_date: The option expires on April 16, 2033. Read SEC document |
| August 20, 2021 Filed Nov 2, 2023 20:09 UTC | enGene Therapeutics Inc. ENGN · Entity 6638 | GrantStock Option (Right to Buy) · Derivative | 10,906 | Not disclosed Strike: $0.88 | Not disclosed |
DisclosureSEC source: 0000929638-23-002989 · form4.xml · derivative · entry 4 Hanson Jason David · CIK 0001368586 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,906 Underlying: Common Shares · 10,906 shares Expires 2031-08-20 F1 · price: On October 31, 2023 (the "Closing Date"), the parties to the Business Combination Agreement, dated as of May 16, 2023 (as amended, the "Business Combination Agreement"), by and among Forbion European Acquisition Corp., a Cayman Islands exempted company and a special purpose acquisition corporation ("FEAC"), enGene Inc., a corporation incorporated under the laws of Canada ("enGene"), and enGene Holdings Inc. (the "Issuer" or "New enGene"), completed the transactions contemplated thereby, pursuant to which (i) each share of FEAC was exchanged on a one for one basis for a share of New enGene, and (ii) each share of enGene was exchanged for 0.1804799669 shares of New enGene, and each of FEAC and enGene became wholly-owned subsidiaries of New enGene. The transactions contemplated by the Business Combination Agreement are referred to herein as the "Business Combination". F2 · price: Pursuant to the terms of the Business Combination, the shareholders of enGene received 0.1804799669 common shares of the Issuer ("Common Shares") for each share of enGene held by them immediately prior to the Closing Date. Upon the Closing of the Business Combination, all outstanding enGene options were assumed by New enGene. enGene options that were issued or available to be issued as of May 16, 2023 were accelerated and become vested and exercisable (if not previously vested and exercisable). The issuance of the securities to the Reporting Person was approved by the Issuer's board of directors in the manner contemplated by Rule 16b-3 under the Securities Exchange Act of 1934, as amended. F6 · price: 6. This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 60,429 common shares of enGene. F6 · derivative.exercise_date: 6. This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 60,429 common shares of enGene. Read SEC document |
| August 20, 2021 Filed Nov 2, 2023 20:09 UTC | enGene Therapeutics Inc. ENGN · Entity 6638 | GrantStock Option (Right to Buy) · Derivative | 524,544 | Not disclosed Strike: $0.88 | Not disclosed |
DisclosureSEC source: 0000929638-23-002989 · form4.xml · derivative · entry 3 Hanson Jason David · CIK 0001368586 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 524,544 Underlying: Common Shares · 524,544 shares Expires 2031-08-20 F1 · price: On October 31, 2023 (the "Closing Date"), the parties to the Business Combination Agreement, dated as of May 16, 2023 (as amended, the "Business Combination Agreement"), by and among Forbion European Acquisition Corp., a Cayman Islands exempted company and a special purpose acquisition corporation ("FEAC"), enGene Inc., a corporation incorporated under the laws of Canada ("enGene"), and enGene Holdings Inc. (the "Issuer" or "New enGene"), completed the transactions contemplated thereby, pursuant to which (i) each share of FEAC was exchanged on a one for one basis for a share of New enGene, and (ii) each share of enGene was exchanged for 0.1804799669 shares of New enGene, and each of FEAC and enGene became wholly-owned subsidiaries of New enGene. The transactions contemplated by the Business Combination Agreement are referred to herein as the "Business Combination". F2 · price: Pursuant to the terms of the Business Combination, the shareholders of enGene received 0.1804799669 common shares of the Issuer ("Common Shares") for each share of enGene held by them immediately prior to the Closing Date. Upon the Closing of the Business Combination, all outstanding enGene options were assumed by New enGene. enGene options that were issued or available to be issued as of May 16, 2023 were accelerated and become vested and exercisable (if not previously vested and exercisable). The issuance of the securities to the Reporting Person was approved by the Issuer's board of directors in the manner contemplated by Rule 16b-3 under the Securities Exchange Act of 1934, as amended. F5 · price: This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 2,906,386 common shares of enGene. F5 · derivative.exercise_date: This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 2,906,386 common shares of enGene. Read SEC document |
| July 30, 2019 Filed Nov 2, 2023 20:09 UTC | enGene Therapeutics Inc. ENGN · Entity 6638 | GrantStock Option (Right to Buy) · Derivative | 30,939 | Not disclosed Strike: $0.88 | Not disclosed |
DisclosureSEC source: 0000929638-23-002989 · form4.xml · derivative · entry 2 Hanson Jason David · CIK 0001368586 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,939 Underlying: Common Shares · 30,939 shares Expires 2029-07-30 F1 · price: On October 31, 2023 (the "Closing Date"), the parties to the Business Combination Agreement, dated as of May 16, 2023 (as amended, the "Business Combination Agreement"), by and among Forbion European Acquisition Corp., a Cayman Islands exempted company and a special purpose acquisition corporation ("FEAC"), enGene Inc., a corporation incorporated under the laws of Canada ("enGene"), and enGene Holdings Inc. (the "Issuer" or "New enGene"), completed the transactions contemplated thereby, pursuant to which (i) each share of FEAC was exchanged on a one for one basis for a share of New enGene, and (ii) each share of enGene was exchanged for 0.1804799669 shares of New enGene, and each of FEAC and enGene became wholly-owned subsidiaries of New enGene. The transactions contemplated by the Business Combination Agreement are referred to herein as the "Business Combination". F2 · price: Pursuant to the terms of the Business Combination, the shareholders of enGene received 0.1804799669 common shares of the Issuer ("Common Shares") for each share of enGene held by them immediately prior to the Closing Date. Upon the Closing of the Business Combination, all outstanding enGene options were assumed by New enGene. enGene options that were issued or available to be issued as of May 16, 2023 were accelerated and become vested and exercisable (if not previously vested and exercisable). The issuance of the securities to the Reporting Person was approved by the Issuer's board of directors in the manner contemplated by Rule 16b-3 under the Securities Exchange Act of 1934, as amended. F4 · price: This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 171,429 common shares of enGene. F4 · derivative.exercise_date: This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 171,429 common shares of enGene. Read SEC document |
| July 09, 2018 Filed Nov 2, 2023 20:09 UTC | enGene Therapeutics Inc. ENGN · Entity 6638 | GrantStock Option (Right to Buy) · Derivative | 137,051 | Not disclosed Strike: $0.88 | Not disclosed |
DisclosureSEC source: 0000929638-23-002989 · form4.xml · derivative · entry 1 Hanson Jason David · CIK 0001368586 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,051 Underlying: Common Shares · 137,051 shares Expires 2028-07-09 F1 · price: On October 31, 2023 (the "Closing Date"), the parties to the Business Combination Agreement, dated as of May 16, 2023 (as amended, the "Business Combination Agreement"), by and among Forbion European Acquisition Corp., a Cayman Islands exempted company and a special purpose acquisition corporation ("FEAC"), enGene Inc., a corporation incorporated under the laws of Canada ("enGene"), and enGene Holdings Inc. (the "Issuer" or "New enGene"), completed the transactions contemplated thereby, pursuant to which (i) each share of FEAC was exchanged on a one for one basis for a share of New enGene, and (ii) each share of enGene was exchanged for 0.1804799669 shares of New enGene, and each of FEAC and enGene became wholly-owned subsidiaries of New enGene. The transactions contemplated by the Business Combination Agreement are referred to herein as the "Business Combination". F2 · price: Pursuant to the terms of the Business Combination, the shareholders of enGene received 0.1804799669 common shares of the Issuer ("Common Shares") for each share of enGene held by them immediately prior to the Closing Date. Upon the Closing of the Business Combination, all outstanding enGene options were assumed by New enGene. enGene options that were issued or available to be issued as of May 16, 2023 were accelerated and become vested and exercisable (if not previously vested and exercisable). The issuance of the securities to the Reporting Person was approved by the Issuer's board of directors in the manner contemplated by Rule 16b-3 under the Securities Exchange Act of 1934, as amended. F3 · price: This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 759,374 common shares of enGene. F3 · derivative.exercise_date: This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 759,374 common shares of enGene. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.